Announcements Trials

Browse Landscape

Phase

Phase NA 5 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 69 Docetaxel 50 Nivolumab 44 Prednisone 34 enzalutamide 30 Gemcitabine 26 Cyclophosphamide 22 Cisplatin 22 Paclitaxel 21 Radiotherapy 19 Carboplatin 19 Bevacizumab 19 Abiraterone Acetate 18 Ipilimumab 17 atezolizumab 14 Magnetic Resonance Spectroscopy 14 fludarabine 13 aldesleukin 13 Sunitinib 13 Interleukin-2 12 avelumab 11 Radiosurgery 11 Pluvicto 11 Filgrastim 11 Everolimus 11 gallium 68 PSMA-11 10 fludarabine phosphate 10 enfortumab vedotin 10 durvalumab 10 cemiplimab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Control Groups × Genitourinary × Clear all

NCT05549778 2023-07-11

PEACe

Jiangnan University

Phase 1/2 Completed

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡